Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 7/20 | 0.88 |
| ▸ | PAX8 | Q06710 | 5/20 | 0.88 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.88 |
| ▸ | MEN1 | O00255 | 9/20 | 0.81 |
| ▸ | THRB | P10828 | 9/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.81 |
| ▸ | BLM | P54132 | 8/20 | 0.81 |
| ▸ | RECQL | P46063 | 7/20 | 0.81 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.81 |
| ▸ | USP2 | O75604 | 4/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.81 |
| ▸ | TOP2A | P11388 | 4/20 | 0.81 |
| ▸ | HTT | P42858 | 4/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyurea SCHEMBL27701805 | 0.95 | S100A4 (0.83) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL27837137 | 0.94 | S100A4 (0.89) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL29338082 | 0.94 | S100A4 (1.00) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL8639928 | 0.94 | S100A4 (1.00) | S100A4PAX8HSP90AA1MEN1THRB | |
| Hydrochloric Acid SCHEMBL11594921 | 0.93 | S100A4 (0.99) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL27493260 | 0.92 | S100A4 (0.87) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL27509581 | 0.91 | S100A4 (0.85) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL24711207 | 0.91 | S100A4 (1.00) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL13524758 | 0.91 | S100A4 (0.89) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL14562338 | 0.91 | S100A4 (0.89) | S100A4PAX8HSP90AA1MEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317974-A | Human IL-12p40 variants and uses thereof | 辛德凯因股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240209101-A1 | COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING | SYNTHEKINE, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240209049-A1 | HETERODIMERIC FC CYTOKINES AND USES THEREOF | SYNTHEKINE, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240199737-A1 | GP130 Binding Molecules and Methods of Use | SYNTHEKINE, INC. | 2024-06-20 | — | — | US | disclosed |
| US-12012457-B1 | IL23R binding molecules and methods of use | SYNTHEKINE, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4370139-A2 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | Synthekine, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240132562-A1 | HETERODIMERIC FC CYTOKINES AND USES THEREOF | SYNTHEKINE, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024086739-A1 | METHODS AND COMPOSITIONS OF IL12 MUTEINS AND IL2 MUTEINS | SYNTHEKINE, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11873349-B1 | Compositions and methods related to IL27 receptor binding | SYNTHEKINE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20240002542-A1 | COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING | SYNTHEKINE, INC. | 2024-01-04 | — | — | US | disclosed |
| US-20210275641-A1 | BIASED IL2 MUTEINS METHODS AND COMPOSITIONS | SYNTHEKINE, INC. | 2021-09-09 | — | — | US | disclosed |
| WO-2021146436-A2 | BIASED IL2 MUTEINS METHODS AND COMPOSITIONS | SYNTHEKINE, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| EP-2408462-A1 | Targeted delivery of chemotherapeutic agents | Sanford-Burnham Medical Research Institute (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108122-A1 | TARGETED DELIVERY OF CHEMOTHERAPEUTIC AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-1877047-A2 | SYSTEMS AND METHODS FOR TREATING HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES, WITH A COMBINATION OF COMPOUNDS, OR A BIFUNCTIONAL COMPOUND,THAT PROVIDES FATTY ACID METABOLISM AND GLYCOLYSIS INHIBITION | The Regents of the University of Colorado (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006118821-A2 | SYSTEMS AND METHODS FOR TREATING HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES, WITH A COMBINATION OF COMPOUNDS, OR A BIFUNCTIONAL COMPOUND,THAT PROVIDES FATTY ACID METABOLISM AND GLYCOLYSIS INHIBITION | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1443962-A2 | METHOD FOR THE TREATMENT OF CARDIOTOXICITY INDUCED BY ANTITUMOR COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003041736-A2 | METHOD FOR THE TREATMENT OF CARDIOTOXICITY INDUCED BY ANTITUMOR COMPOUNDS | PHARMACIA & UPJOHN COMPANY (IT) | 2003-05-22 | — | — | WO | disclosed |
| US-20030096823-A1 | Method for the treatment of cardiotoxicity induced by antitumor compounds | PHARMACIA ITALIA S.P.A. (IT) | 2003-05-22 | — | — | US | disclosed |
| EP-0392487-A2 | Stabilized composition of anthracyclines | Takeda Chemical Industries, Ltd. (JP) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275641-A1 | BIASED IL2 MUTEINS METHODS AND COMPOSITIONS | IL2, IL2RA, IL36G | S100A4 2948/4885PAX8 2590/4885HSP90AA1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.